Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

CYBERDYNE Inc

Healthcare US CYBQF

1.865USD
0.00(0%)

Last update at 2026-06-18T20:00:00Z

Day Range

1.551.55
LowHigh

52 Week Range

1.072.05
LowHigh

Fundamentals

  • Previous Close 1.86
  • Market Cap327.25M
  • Volume440
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA112.00M
  • Revenue TTM4108.00M
  • Revenue Per Share TTM19.46
  • Gross Profit TTM 2509.00M
  • Diluted EPS TTM-0.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Income before tax -879.00000M -1141.00000M 53.00M -379.00000M 408.00M
Minority interest 129.00M 172.00M 95.00M 24.00M 10.00M
Net income -577.00000M -1476.00000M -298.00000M -492.00000M -59.00000M
Selling general administrative 2804.00M 3251.00M 2406.00M 1787.00M 1471.00M
Selling and marketing expenses - 429.00M - - -
Gross profit 2373.00M 2393.00M 1791.00M 1462.00M 1284.00M
Reconciled depreciation 592.00M 677.00M 627.00M 473.00M 463.00M
Ebit -576.00000M -1435.00000M -28.00000M -490.00000M 51.00M
Ebitda 16.00M -758.00000M 599.00M -17.00000M 514.00M
Depreciation and amortization 592.00M 677.00M 627.00M 473.00M 463.00M
Non operating income net other - - - - -
Operating income -926.00000M -2018.00000M -1145.00000M -868.00000M -700.00000M
Other operating expenses 5310.00M 6372.00M 4435.00M 3019.00M 2574.00M
Interest expense 303.00M 482.00M 193.00M 4.00M 2.00M
Tax provision -174.00000M 507.00M 446.00M 136.00M 479.00M
Interest income 539.00M 543.00M 1312.00M 398.00M 770.00M
Net interest income 236.00M 61.00M 1119.00M 394.00M 768.00M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -174.00000M 507.00M 446.00M 136.00M 479.00M
Total revenue 4384.00M 4354.00M 3289.00M 2150.00M 1875.00M
Total operating expenses 3299.00M 4411.00M 2937.00M 2331.00M 1983.00M
Cost of revenue 2011.00M 1961.00M 1498.00M 688.00M 591.00M
Total other income expense net 47.00M 877.00M 1198.00M 489.00M 1108.00M
Discontinued operations - - - - -
Net income from continuing ops -705.00000M -1648.00000M -393.00000M -515.00000M -71.00000M
Net income applicable to common shares - - - -492.00000M -59.00000M
Preferred stock and other adjustments - - - - -
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Total assets 48547.00M 49999.00M 50187.00M 49459.00M 48119.00M
Intangible assets 45.00M 48.00M 80.00M 35.00M 38.00M
Earning assets - - - - -
Other current assets 178.00M 139.00M 308.00M 455.00M 349.00M
Total liab 8954.00M 9522.00M 8204.00M 6002.00M 4333.00M
Total stockholder equity 39575.00M 40752.00M 42101.00M 43419.00M 43776.00M
Deferred long term liab - - - - -
Other current liab 384.00M 386.00M 365.00M 376.00M 275.00M
Common stock 10.00M 10.00M 10.00M 10.00M 10.00M
Capital stock 10.00M 10.00M 10.00M 10.00M 10.00M
Retained earnings -801.00000M -95.00000M 1381.00M 1685.00M 2177.00M
Other liab - - 6480.00M 4751.00M 3369.00M
Good will 1766.00M 2134.00M 2531.00M 2104.00M 57.00M
Other assets -1.00000M - 13807.00M -1.00000M 1.00M
Cash 6824.00M 5155.00M 7801.00M 5677.00M 6704.00M
Cash and equivalents - - - - -
Total current liabilities 1085.00M 1236.00M 1291.00M 828.00M 635.00M
Current deferred revenue - - - - -
Net debt -6390.00000M -4523.00000M -7132.00000M -5102.00000M -6283.00000M
Short term debt 168.00M 244.00M 236.00M 152.00M 92.00M
Short long term debt 22.00M 84.00M 89.00M 34.00M 31.00M
Short long term debt total 434.00M 632.00M 669.00M 575.00M 421.00M
Other stockholder equity 40366.00M 41623.00M 40710.00M 41724.00M 41589.00M
Property plant equipment - - 14382.00M 14345.00M 13018.00M
Total current assets 16758.00M 18469.00M 19147.00M 22865.00M 27220.00M
Long term investments - - - - -
Net tangible assets - - - 41280.00M 43681.00M
Short term investments 8033.00M 11504.00M 9507.00M 15151.00M 19007.00M
Net receivables 800.00M 674.00M 540.00M 493.00M 352.00M
Long term debt 15.00M 22.00M 21.00M 34.00M 49.00M
Inventory 923.00M 997.00M 991.00M 1089.00M 808.00M
Accounts payable 533.00M 606.00M 690.00M 300.00M 268.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - -786.00000M - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 15835.00M 11699.00M 9673.00M 15255.00M 19067.00M
Deferred long term asset charges - - - - -
Non current assets total 31790.00M 31530.00M 31040.00M 26594.00M 20898.00M
Capital lease obligations 397.00M 526.00M 559.00M 507.00M 341.00M
Long term debt total - - - - -
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Investments 2325.00M -2075.00000M 2173.00M 2153.00M -1715.00000M
Change to liabilities - - 0.00000M -76.00000M 45.00M
Total cashflows from investing activities 2325.00M -2075.00000M - -1788.00000M -2794.00000M
Net borrowings -5.00000M -10.00000M -165.00000M -47.00000M -9.00000M
Total cash from financing activities -216.00000M 160.00M 14.00M 1248.00M 617.00M
Change to operating activities - - - 87.00M -788.00000M
Net income -879.00000M -1476.00000M 53.00M -379.00000M 408.00M
Change in cash 1669.00M -2646.00000M 2124.00M -1027.00000M -2932.00000M
Begin period cash flow 5155.00M 7801.00M 5677.00M 6704.00M 9636.00M
End period cash flow 6824.00M 5155.00M 7801.00M 5677.00M 6704.00M
Total cash from operating activities -430.00000M -850.00000M -143.00000M -564.00000M -775.00000M
Issuance of capital stock - - - - -
Depreciation 592.00M 677.00M 627.00M 473.00M 463.00M
Other cashflows from investing activities 1.00M 24.00M - -18.00000M -4.00000M
Dividends paid - - - - -
Change to inventory 74.00M -6.00000M 98.00M -281.00000M 24.00M
Change to account receivables -126.00000M -134.00000M -275.00000M 29.00M -88.00000M
Sale purchase of stock 0.00000M 0.00000M -1188.00000M - -
Other cashflows from financing activities -211.00000M 170.00M 1214.00M 1295.00M 646.00M
Change to netincome - - -674.00000M -417.00000M -839.00000M
Capital expenditures 305.00M 224.00M 509.00M 1776.00M 1075.00M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -125.00000M -848.00000M 202.00M -328.00000M -19.00000M
Stock based compensation - - - - -
Other non cash items -18.00000M 797.00M -1025.00000M -330.00000M -1627.00000M
Free cash flow -735.00000M -1074.00000M -652.00000M -2340.00000M -1850.00000M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CYBQF
CYBERDYNE Inc		 - -% 1.86 - 238.10 0.08 1.30 13.10 88.01
ABT
Abbott Laboratories		 -0.58 0.66% 87.83 25.97 17.24 3.57 3.20 3.81 16.75
SYK
Stryker Corporation		 -3.11 1.01% 304.69 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 -0.07 0.09% 79.27 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 -0.96 2.12% 44.33 31.49 17.24 4.41 3.65 4.88 19.19

Reports Covered

Stock Research & News

View All

Profile

CYBERDYNE Inc. researches, develops, produces, sell, leases, and maintains robotic equipment and systems for medical and welfare in Japan, the United States, Europe, the Middle East, Africa, and the Asia Pacific countries. The company offers Hybrid Assistive Limb (HAL) for medical use in lower limb and single joint type; non-medical HAL for lower limb, single joint type, and lumbar type; HAL peripherals; cleaning robots; transportation robots for various transportation tasks in factories, offices, and other indoor environments; Acoustic X, a high-speed light pulse LED array light source that enables real time photoacoustic imaging; and CYIN for living support, which is an interface that uses biological information that can be controlled voluntarily outside of muscle activities. It also provides Cybernics Treatment, a treatment that uses HAL to enhance and regenerate the function of the wearer for spinal cord injury, stroke, neuromuscular diseases, etc.; Neuro HALFIT for enhancement of brain-nerve-musculoskeltal system; MTX Neuro HAL Plus to enhance the performance of the athletes' brain-nerve functions; and Neuro HALFIT at home for enhancement of physical functions. In addition, the company provides rescue support in disaster sites, and heavy labor support for factories and plants, as well as engages in the entertainment business. CYBERDYNE Inc. was incorporated in 2004 and is headquartered in Tsukuba, Japan.

CYBERDYNE Inc

2-2-1, Gakuen-Minami, Tsukuba, Japan, 305-0818

Key Executives

Name Title Year Born
Mr. Yoshiyuki Sankai Chairman, Pres & CEO 1958
Mr. Shinji Uga Head of Corp. Unit & Director 1970
Dr. Yoshiyuki Sankai Chairman, President & CEO 1958
Mr. Shinji Honda Executive Director & COO 1965

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions